Skip to content

Oxacillin Sodium

FDA-approved product (capsule, oral), marketed as Bactocill, Bactocill In Plastic Container, Oxacillin Sodium and 1 more.

Registered studies
50+
Lab records
22
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Oxacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta-lactamase resistant penicillins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CF04

Repurposing investigation

Oxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 9 of 22 lab records
Show the 22 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Staphylococcus Aureus Bacteremia Antibiotic Treatment Options

    NCT01792804 · start 2013-12

    Registered record
    Registry ID
    NCT01792804
    Conditions
    Staphylococcus Aureus Infection
    Interventions
    Trimethoprim-Sulfamethoxazole; Clindamycin; Linezolid; Flucloxacillin; Cloxacillin; Vancomycin; Daptomycin; Cefazolin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12
    Completion
    2020-03-26
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus Aureus Infection
    InterventionTrimethoprim-Sulfamethoxazole; Clindamycin; Linezolid; Flucloxacillin +4 more
    PhasePhase 3
    Registry statusCompleted
  • Adjunctive Clindamycin for Cellulitis: C4C Trial.

    NCT01876628 · start 2013-10

    Registered record
    Registry ID
    NCT01876628
    Conditions
    Cellulitis
    Interventions
    Flucloxacillin; Clindamycin; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2016-03
    Enrolment
    410

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCellulitis
    InterventionFlucloxacillin; Clindamycin; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted
  • Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.

    NCT01875263 · start 2013-05

    Registered record
    Registry ID
    NCT01875263
    Conditions
    Staphylococcus
    Interventions
    Cloxacilin; Cloxacillin; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2014-11
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcus
    InterventionCloxacilin; Cloxacillin; Levofloxacin
    PhasePhase 3
    Registry statusTerminated
  • Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

    NCT01191840 · start 2011-02

    Registered record
    Registry ID
    NCT01191840
    Conditions
    Bacteremia
    Interventions
    Vancomycin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-03-04
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionVancomycin; Vancomycin
    PhasePhase 2
    Registry statusCompleted
  • Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

    NCT01104662 · start 2010-04-19

    Registered record
    Registry ID
    NCT01104662
    Conditions
    Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
    Interventions
    Vancomycin; Daptomycin; Semi-Synthetic Penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-04-19
    Completion
    2012-06-12
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment
    InterventionVancomycin; Daptomycin; Semi-Synthetic Penicillin
    PhasePhase 4
    Registry statusTerminated
  • Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

    NCT01184872 · start 2010-03

    Registered record
    Registry ID
    NCT01184872
    Conditions
    Infections
    Interventions
    Daptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionDaptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs)
    PhasePhase 3
    Registry statusCompleted
  • Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

    NCT00711802 · start 2008-07-23

    Registered record
    Registry ID
    NCT00711802
    Conditions
    Skin Diseases, Infectious
    Interventions
    Daptomycin; Standard of Care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07-23
    Completion
    2013-10-11
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious
    InterventionDaptomycin; Standard of Care (SOC)
    PhasePhase 4
    Registry statusCompleted
  • Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis

    NCT00716183 · start 2008-07

    Registered record
    Registry ID
    NCT00716183
    Conditions
    Mastitis
    Interventions
    Lactobacillus salivarius HN6; Lactobacillus reuteri CR20; Lactobacillus fermentum LC40; Beta-lactam antibiotic
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2009-05
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMastitis
    InterventionLactobacillus salivarius HN6; Lactobacillus reuteri CR20; Lactobacillus fermentum LC40; Beta-lactam antibiotic
    PhasePhase 2 / Phase 3
    Registry statusCompleted
  • Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients

    NCT00885300 · start 2008-01

    Registered record
    Registry ID
    NCT00885300
    Conditions
    Double Lumen Infection; Hemodialysis
    Interventions
    cloxacillin; heparin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-01
    Completion
    2008-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDouble Lumen Infection; Hemodialysis
    Interventioncloxacillin; heparin
    PhaseNot applicable
    Registry statusCompleted
  • Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

    NCT00428844 · start 2007-06-26

    Registered record
    Registry ID
    NCT00428844
    Conditions
    Osteomyelitis
    Interventions
    daptomycin; daptomycin; vancomycin; teicoplanin; nafcillin; oxacillin; flucloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06-26
    Completion
    2010-06-23
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventiondaptomycin; daptomycin; vancomycin; teicoplanin +3 more
    PhasePhase 2
    Registry statusCompleted
  • Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant

    NCT00518076 · start 2006-09

    Registered record
    Registry ID
    NCT00518076
    Conditions
    Staphylococcal Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2006-09
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown
  • Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia

    NCT01166932 · start 2005-04

    Registered record
    Registry ID
    NCT01166932
    Conditions
    Community-Acquired Pneumonia
    Interventions
    Amoxycillin/clavulanic acid; ceftriaxone/oxacillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-04
    Completion
    2009-04
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-Acquired Pneumonia
    InterventionAmoxycillin/clavulanic acid; ceftriaxone/oxacillin
    PhasePhase 4
    Registry statusCompleted
  • Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)

    NCT00358371 · start 2005-01-06

    Registered record
    Registry ID
    NCT00358371
    Conditions
    Infections, Bacterial
    Interventions
    flucloxacillin 250 mg; flucloxacillin 500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-01-06
    Completion
    2005-02-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial
    Interventionflucloxacillin 250 mg; flucloxacillin 500 mg
    PhasePhase 1
    Registry statusCompleted
  • Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

    NCT00077675 · start 2004-02

    Registered record
    Registry ID
    NCT00077675
    Conditions
    Infections, Gram-positive Bacterial
    Interventions
    Telavancin; vancomycin or antistaphylococcal penicillin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-09
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Gram-positive Bacterial
    InterventionTelavancin; vancomycin or antistaphylococcal penicillin
    PhasePhase 2
    Registry statusCompleted
  • Determinants of Warfarin Metabolism

    NCT00162474 · start 2003-09

    Registered record
    Registry ID
    NCT00162474
    Conditions
    Healthy
    Interventions
    Warfarin; Phenytoin; Losartan & Hydrochlorothiazide; Flurbiprofen; Siponimod; Dicloxacillin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2003-09
    Completion
    2030-12
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionWarfarin; Phenytoin; Losartan & Hydrochlorothiazide; Flurbiprofen +2 more
    PhaseNot applicable
    Registry statusRecruiting